Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Benoît Roch
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial
Abstract The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvant chemoimmunotherapy guided by multidisciplinary team assessments during the neoadjuvant period.
Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring
Lung cancer is the third most common malignancy in the United States and remains the leading cause of cancer-related mortality worldwide. Despite ongoing advances in diagnosis and therapy, survival rates for patients with lung cancer remain unsatisfactory (). In recent years, interest in liquid biopsy (LB) has grown substantially, particularly following the approval of LB testing in lung cancer.
Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy
Open AccessArticle by Stefania Cuzzubbo 1,2, Benoit Roch 3, Guillaume Darrasse-Jèze 4, Benoit Hosten 5, Manon Leclercq 3, Nicolas Vignal 5, Claire Banissi 2, Eric Tartour 6 and Antoine F.
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Kaplan-Meier estimates of survival of non-small cell lung patients receiving anti-PD-1 immune-checkpoint inhibitors, according to body-weight loss in the three previous months; a: progression-free survival; b: overall survival. Fig.
An in vivo study of the impact of deficiency in the DNA repair proteins PAXX and XLF on development and maturation of the hemolymphoid system
Stefania Musilli1, Vincent Abramowski, Benoit Roch and Jean-Pierre de Villartay2 Laboratory of Genome Dynamics in the Immune System, Imagine Institute, INSERM UMR 1163, Université de Paris, 75015 Paris, France ↵2 To whom correspondence should be addressed: INSERM UMR1163, Equipe Labellisée La Ligue, Institut Imagine, 24 bd. du Montparnasse, 75015 Paris, France. E-mail: devillartay{at}gmail.com.
An in vivo study of the impact of deficiency in the DNA repair proteins PAXX and XLF on the development and maturation of the hemo-lymphoid system
Stefania Musilli1, Vincent Abramowski1, Benoit Roch1 and Jean-Pierre de Villartay2* 1Institut Imagine, INSERM U1163, France 2INSERM U768, Hopital Necker-Enfants Malades, France ↵* Corresponding author; email: jean-pierre.de-villartay{at}inserm.fr Author contributions: S.M. and V.A. data curation; S.M., V.A., and B.R. formal analysis; S.M. and V.A. investigation; S.M. and J.-P.d.V. writing-original draft; J.-P.d.V. conceptualization; J.-P.d.V. supervision.
Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
For most patients, tumor burden and reduced quality of life in relation with lung cancer itself were major drivers of the decision-making process. There was a balance between two different attitudes: making a decision to undergo a new line of chemotherapy or starting a psychological process in order to accept end of life. Choosing between these two attitudes allowed the patient to keep the matter of palliative care at a distance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Benoît
Contact Benoît, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack